Family Blood Pressure Program - HyperGEN

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Donna K. Arnett, PhD, Professor, Chair, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00005267
First received: May 25, 2000
Last updated: June 18, 2012
Last verified: June 2012
  Purpose

To map and identify the major genetic determinants of hypertension and to study possible interactions between genetic and non-genetic factors in defined populations. HyperGEN initially consisted of a nine grant network, which in turn is part of an NHLBI initiative, the Family Blood Pressure Program (FBPP) consisting of four networks.


Condition
Cardiovascular Diseases
Heart Diseases
Hypertension

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Biospecimen Retention:   Samples With DNA

Tissue suitable for DNA extraction


Enrollment: 3604
Study Start Date: September 1995
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

(A) sample of hypertensive sibships with at least two members diagnosed with hypertension before the age of 60 (probands); (B) random sample of age-matched persons from the same base populations, from which normotensive controls could be drawn; (C) unmedicated, normotensive adult offspring of one of the hypertensive siblings.

Criteria

Inclusion criteria for probands: Onset of hypertension by age 60 years and the presence of at least one additional hypertensive sibling who was willing to participate. Hypertension was defined according to systolic BP ≥140 or diastolic BP ≥90 in at least two different evaluations, or treatment for hypertension. Volunteers with type 1 diabetes or renal failure were excluded.

Inclusion criteria for subsequent recruits: Criteria as indicated in Study Population Description (i.e., criteria based on familial relationships, hypertension and antihypertensive medication status).

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005267

Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Principal Investigator: Donna Arnett University of Alabama at Birmingham
Principal Investigator: John Eckfeldt University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: R.Curtis Ellison Boston University
Principal Investigator: Steven Hunt University of Utah
Principal Investigator: Jean-Marc Lalouel University of Utah
Principal Investigator: Cora Lewis University of Alabama at Birmingham
Principal Investigator: Kari North University of North Carolina
Principal Investigator: James Pankow University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: Dabeeru Rao Washington University Early Recognition Center
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Liu CT, Monda KL, Taylor KC, Lange L, Demerath EW, Palmas W, Wojczynski MK, Ellis JC, Vitolins MZ, Liu S, Papanicolaou GJ, Irvin MR, Xue L, Griffin PJ, Nalls MA, Adeyemo A, Liu J, Li G, Ruiz-Narvaez EA, Chen WM, Chen F, Henderson BE, Millikan RC, Ambrosone CB, Strom SS, Guo X, Andrews JS, Sun YV, Mosley TH, Yanek LR, Shriner D, Haritunians T, Rotter JI, Speliotes EK, Smith M, Rosenberg L, Mychaleckyj J, Nayak U, Spruill I, Garvey WT, Pettaway C, Nyante S, Bandera EV, Britton AF, Zonderman AB, Rasmussen-Torvik LJ, Chen YD, Ding J, Lohman K, Kritchevsky SB, Zhao W, Peyser PA, Kardia SL, Kabagambe E, Broeckel U, Chen G, Zhou J, Wassertheil-Smoller S, Neuhouser ML, Rampersaud E, Psaty B, Kooperberg C, Manson JE, Kuller LH, Ochs-Balcom HM, Johnson KC, Sucheston L, Ordovas JM, Palmer JR, Haiman CA, McKnight B, Howard BV, Becker DM, Bielak LF, Liu Y, Allison MA, Grant SF, Burke GL, Patel SR, Schreiner PJ, Borecki IB, Evans MK, Taylor H, Sale MM, Howard V, Carlson CS, Rotimi CN, Cushman M, Harris TB, Reiner AP, Cupples LA, North KE, Fox CS. Genome-wide association of body fat distribution in African ancestry populations suggests new loci. PLoS Genet. 2013 Aug;9(8):e1003681. doi: 10.1371/journal.pgen.1003681. Epub 2013 Aug 15.

Responsible Party: Donna K. Arnett, PhD, Professor, Chair, Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00005267     History of Changes
Other Study ID Numbers: 1151, 5R01HL055673-15
Study First Received: May 25, 2000
Last Updated: June 18, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Hypertension
Vascular Diseases

ClinicalTrials.gov processed this record on September 22, 2014